General disorders and administration site conditions Fatigue 52 14 4 45 16 4 Metabolism and nutrition disorders Anorexia 52 8 1 38 5 <1 Respiratory, thoracic and mediastinal disorders Dyspnoea 41 17 11 35 15 11 Cough 33 4 0 29 2 0 Infections and infestations* Infection 24 4 0 15 2 0 Eye disorders Conjunctivitis 12 <1 0 2 <1 0 Keratoconjunctivitis sicca 12 0 0 3 0 0 * severe infections, with or without neutropenia, have included pneumonia, sepsis and cellulitis. In another double-blind, randomised, placebo-controlled Phase III study (BO18192) conducted in 889 patients with advanced, recurrent or metastatic NSCLC following first-line standard platinum-based chemotherapy, no new safety signals were identified.
General disorders and administration site conditions Fatigue 52 14 4 45 16 4 Metabolism and nutrition disorders Anorexia 52 8 1 38 5 <1 Respiratory, thoracic and mediastinal disorders Dyspnoea Cough 41 33 17 4 11 0 35 29 15 2 11 0 Infections and infestations* Infection 24 4 0 15 2 0 Eye disorders Conjunctivitis Keratoconjunctivitis sicca 12 12 <1 0 0 0 2 3 <1 0 0 0 * severe infections, with or without neutropenia, have included pneumonia, sepsis and cellulitis. In another double-blind, randomised, placebo-controlled Phase III study (BO18192) conducted in 889 patients with advanced, recurrent or metastatic NSCLC following first-line standard platinum-based chemotherapy, no new safety signals were identified.
auspar-erlotinib-130107-pi.docx